DRG Epidemiology's coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of malignant melanoma for each country as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the major mature pharmaceutical markets.

DRG Epidemiology's malignant melanoma forecast will answer the following questions:

  • How will improvements in survival change the number of people diagnosed with malignant melanoma per year?
  • How will decreasing recurrence risk change the number of people living with malignant melanoma?
  • Of all people diagnosed with malignant melanoma, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of malignant melanoma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following malignant melanoma patient populations:

  • Diagnosed incident cases by stage.
  • Diagnosed prevalent cases by resectability status.
  • First recurrence by site.
  • First regional recurrence by resectability status.
  • Second recurrence by site.
  • Second regional recurrence by resectability status.
  • First-line unresectable BRAF+ve and BRAF-ve DTP subpopulation(s).
  • Adjuvant drug-treatable population.
  • Other lines of treatment.

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Malignant Melanoma - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Diagnosed Incidence of Malignant Melanoma per 100,000 Among People of All Ages in 2020 and 2040
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Malignant Melanoma over the Next 20 Years
      • Analysis of the Diagnosed Incident Cases of Malignant Melanoma in 2020 by Stage Distribution
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • Stage Distribution
      • Recurrent Incident Cases
      • Diagnosed Prevalent Cases
      • Drug-Treatable Populations
      • Drug-Treated Populations
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Malignant Melanoma
        • Studies Excluded from the Analysis of Malignant Melanoma
      • Risk/Protective Factors
        • Risk/Protective Factors for Malignant Melanoma
      • Bibliography
      • Glossary

Author(s): Surup Dey; Swarali Tadwalkar

Surup Dey has a background in medical laboratory science from Christian Medical College, Vellore with a postgraduate degree in Public Health specializing in Epidemiology from Manipal University. He has expertise in Real World Data analysis and in conducting fully documented systematic reviews on the epidemiology of various diseases and develop forecast models.

Prior to joining DRG, he worked for 2 years in the field of medical diagnostic microbiology and was also involved in the diagnosis of rare hematological disorders. He was involved in epidemiological and operational research related to tuberculosis and health system as well as conducted situational assessment of HIV counselling and testing services in the private health facilities in the four districts of West Bengal, India.

Swarali joined Decision Resources Group (DRG) in 2016 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with her particular interests in the oncology space.

Prior to joining DRG, she has been extensively involved in primary and secondary healthcare research. Her experience involves projects in digital health, health policy and management, and health economics and outcomes research (HEOR). She has also coordinated various non-governmental public health projects focusing in hepatitis and human papilloma virus treatment access. Swarali holds a Masters in Public Health (Epidemiology) degree from the University of South Florida, Tampa.

Related Reports

Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/ME...

View Details

Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /...

View Details

Malignant Melanoma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer pati...

View Details